AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that it will assume full development and commercial responsibility for its collaboration with Galapagos (Euronext: GLPG) to discover and develop new therapies to treat cystic fibrosis (CF).

New Assays empower Clinicians to more quickly make the right diagnosis at the point-of-care and prescribe the right treatment

Reducing prescription drug prices for patients while still encouraging pharmaceutical research and development is a difficult problem to solve politically, the founder of a web-based think tank said in the wake of attack ads against candidates.

The American Brain Tumor Association (ABTA), the nation's first nonprofit organization dedicated to brain tumor education and research, is now accepting Letters of Intent (LOI) for three research funding opportunities.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack.

Video and phone sessions can close the gap between academic-based medical settings where cancer patients are more likely to receive genetic counseling and other care settings where they may not, Penn Medicine News reported.

A study presented at the European Association for the Study of Diabetes found that patients are not storing their insulin at the recommended temperature ranges.

A genetic counseling group announced earlier this week its support for genetic testing of children during the adoption process.

The Leukemia & Lymphoma Society (LLS) continues to lead cutting-edge research to advance treatments for myeloma and lymphoma. Adding to the momentum, the organization announced a $1,175,000 commitment by the Schwartz Ward Family Foundation (SWFF) of Chicago to support two unique research initiatives including a novel therapy for a rare form of lymphoma and an innovative immunotherapy approach for multiple myeloma.

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of patients with B-cell malignancies.

Long-term care facilities play a critical role in caring for the needs of a growing aging population with a lengthening lifespan.

Agreement Establishes a New Stronghold in a Rapidly Expanding Fertility Market

Montefiore’s outstanding stroke care has been recognized by an Advanced Comprehensive Stroke Center designation, meaning that the highest standards of lifesaving stroke care are close to home for millions of New Yorkers.

Research shows adding Abbott's High Sensitive Troponin-I diagnostic test to doctors' existing standard of care can help more accurately determine a person's chances of a heart attack or other cardiac event potentially months to years in advance

AbbVie, a research-based global biopharmaceutical company, today announced a donation of $5 million to Family Reach to support the organization's efforts to alleviate the financial burden of cancer on pediatric patients and families across the United States.

Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality™ (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients two years of age and older.

Astrazeneca issued the following announcement on Sept. 13.AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved LUMOXITI™ (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Agreement Adds Continuous Glucose Data Fueling Diabetes Management Insights

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions